BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Strader DB, Seeff LB. A brief history of the treatment of viral hepatitis C. Clin Liver Dis. 2012;1:6-11. [PMID: 31186837 DOI: 10.1002/cld.1] [Cited by in Crossref: 28] [Cited by in F6Publishing: 16] [Article Influence: 2.8] [Reference Citation Analysis]
Number Citing Articles
1 Hayes CN, Chayama K. Interferon stimulated genes and innate immune activation following infection with hepatitis B and C viruses: ISGs in HCV and HBV Infection. J Med Virol 2017;89:388-96. [DOI: 10.1002/jmv.24659] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
2 Gao LH, Nie QH, Zhao XT. Drug-Drug Interactions of Newly Approved Direct-Acting Antiviral Agents in Patients with Hepatitis C. Int J Gen Med 2021;14:289-301. [PMID: 33536776 DOI: 10.2147/IJGM.S283910] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 El-yazbi AF, Khalifa Y, Elkhatib MA, El-yazbi AF. Green analytical method for the determination of sofosbuvir, ledipasvir, ribavirin and complex silymarin flavonoids simultaneously in biological fluids. Microchemical Journal 2021;164:105964. [DOI: 10.1016/j.microc.2021.105964] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
4 Leoni MC, Ustianowski A, Farooq H, Arends JE. HIV, HCV and HBV: A Review of Parallels and Differences. Infect Dis Ther 2018;7:407-19. [PMID: 30182282 DOI: 10.1007/s40121-018-0210-5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
5 Sharafi H, Alavian SM. Hepatitis C resistance to NS5A inhibitors: Is it going to be a problem? World J Hepatol 2018; 10(9): 543-548 [PMID: 30310532 DOI: 10.4254/wjh.v10.i9.543] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
6 Younossi Z, Henry L. Systematic review: patient-reported outcomes in chronic hepatitis C--the impact of liver disease and new treatment regimens. Aliment Pharmacol Ther. 2015;41:497-520. [PMID: 25616122 DOI: 10.1111/apt.13090] [Cited by in Crossref: 124] [Cited by in F6Publishing: 123] [Article Influence: 17.7] [Reference Citation Analysis]
7 Siddiqi HK, Schlendorf KH. Hepatitis C Positive Organ Donation in Heart Transplantation. Curr Transplant Rep 2021;:1-9. [PMID: 34786324 DOI: 10.1007/s40472-021-00350-1] [Reference Citation Analysis]
8 Spera AM. Safety of direct acting antiviral treatment for hepatitis C in oncologic setting: A clinical experience and a literature review. World J Hepatol 2022; 14(3): 525-534 [DOI: 10.4254/wjh.v14.i3.525] [Reference Citation Analysis]
9 Chávez-tapia NC, Ridruejo E, de Mattos AA, Bessone F, Daruich J, Sánchez-ávila JF, Cheinquer H, Zapata R, Uribe M, Bosques-padilla F, Gadano A, Soza A, Dávalos-moscol M, Marroni C, Muñoz-espinoza L, Castro-narro G, Paraná R, Méndez-sánchez N. An update on the management of hepatitis C: guidelines for protease inhibitor-based triple therapy from the Latin American Association for the Study of the Liver. Annals of Hepatology 2013;12:S3-S35. [DOI: 10.1016/s1665-2681(19)31404-8] [Cited by in Crossref: 6] [Article Influence: 0.7] [Reference Citation Analysis]
10 Puchades Renau L, Berenguer M. Introduction to hepatitis C virus infection: Overview and history of hepatitis C virus therapies: Overview and history of hepatitis C therapies. Hemodialysis International 2018;22:S8-S21. [DOI: 10.1111/hdi.12647] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
11 Chayama K, Mitsui F, Hayes CN. Optimizing triple therapy and IFN/RBV-free regimens for hepatitis C virus infection. Expert Rev Gastroenterol Hepatol 2015;9:21-30. [PMID: 25220206 DOI: 10.1586/17474124.2015.960394] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
12 Link JO, Taylor JG, Trejo-Martin A, Kato D, Katana AA, Krygowski ES, Yang ZY, Zipfel S, Cottell JJ, Bacon EM, Tran CV, Yang CY, Wang Y, Wang KW, Zhao G, Cheng G, Tian Y, Gong R, Lee YJ, Yu M, Gorman E, Mogalian E, Perry JK. Discovery of velpatasvir (GS-5816): A potent pan-genotypic HCV NS5A inhibitor in the single-tablet regimens Vosevi® and Epclusa®. Bioorg Med Chem Lett 2019;29:2415-27. [PMID: 31230974 DOI: 10.1016/j.bmcl.2019.04.027] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 4.7] [Reference Citation Analysis]
13 Yang S, K R J, Lim S, Choi TG, Kim JH, Akter S, Jang M, Ahn HJ, Kim HY, Windisch MP, Khadka DB, Zhao C, Jin Y, Kang I, Ha J, Oh BC, Kim M, Kim SS, Cho WJ. Structure-Based Discovery of Novel Cyclophilin A Inhibitors for the Treatment of Hepatitis C Virus Infections. J Med Chem 2015;58:9546-61. [PMID: 26613291 DOI: 10.1021/acs.jmedchem.5b01064] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
14 Vivancos M, Moreno A, Quereda C. Tratamiento del virus de la hepatitis C con antivirales de acción directa: Aspectos prácticos y situación actual. Revista Clínica Española 2018;218:29-37. [DOI: 10.1016/j.rce.2017.07.006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
15 Tinè F, Attanasio M, Muggeo VMR, Crainiceanu CM. Evidence of bias in randomized clinical trials of hepatitis C interferon therapies. Clin Trials 2017;14:483-8. [PMID: 28670909 DOI: 10.1177/1740774517715447] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
16 Hayes CN, Chayama K. Why highly effective drugs are not enough: the need for an affordable solution to eliminating HCV. Expert Rev Clin Pharmacol 2017;10:583-94. [PMID: 28374641 DOI: 10.1080/17512433.2017.1313111] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
17 Fabrizi F, Messa P. Managing hepatitis C therapy failures and chronic kidney disease. Expert Rev Clin Pharmacol 2018;11:1135-42. [PMID: 30309263 DOI: 10.1080/17512433.2018.1534202] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
18 Tao T, Jiang X, Chen Y, Song Y. Efficacy and Safety of Ledipasvir/Sofosbuvir with and without Ribavirin in Patients with Chronic Hepatitis C Virus Genotype 1 Infection: a meta-analysis. Int J Infect Dis 2017;55:56-71. [PMID: 28040553 DOI: 10.1016/j.ijid.2016.12.023] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 2.7] [Reference Citation Analysis]